US Markets
Home›US Markets›M&A & Deals›Royalty Pharma to pay up to $425 million for Neurimmun…
Royalty Pharma to pay up to $425 million for Neurimmune deal tied to AZN asset
The payment structure includes $125 million upfront, another $125 million in cash in Q1 2027, and up to $175 million more linked to clinical and regulatory milestones.
Royalty Pharma plc agreed to acquire a portion of Neurimmune's royalty interest tied to AstraZeneca PLC's (AZN) candidate cliramitug, in a deal that can pay Neurimmune up to $425 million. Under the agreement, Royalty Pharma will pay $125 million upfront. In the first quarter of 2027, Royalty Pharma will pay an additional $125 million in cash, with the remaining $175 million dependent on clinical and regulatory milestones, according to Yahoo Finance.
Royalty Pharma will receive a 3% to 4% royalty on global net sales, the outlet said. Cliramitug is in Phase 3 of the DepleTTR-CM trial, with data readouts expected in 2028, and is aimed at transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Yahoo Finance also highlighted that the therapeutic approach is designed as a TTR-fibril-depleting antibody intended to clear existing amyloid deposits, unlike current approved treatments that focus on slowing progression. The article further notes a timing mismatch in the companies it compares, with AstraZeneca reporting Q2 and H1 2026 results while Royalty Pharma’s latest report covers Q1 2026.